Written by: Dr. Akash Chandawarkar, Board Certified Plastic Surgeon, Mirror Plastic Surgery | Last updated: September 9, 2026
What This Article Covers
This article explains how Avéli works, what the main clinical study shows, how long results last, how it compares to other cellulite treatments, and who makes a good candidate.
The Mechanism: How Avéli Releases Fibrous Septa
Avéli is a minimally invasive, FDA-cleared procedure that uses a small handheld device to identify, release, and confirm the cutting of the fibrous bands (septa) that tether skin downward and create cellulite dimples. The device mechanically severs these bands so the skin surface smooths, creating a structural correction that directly targets the cause of dimples.
Cellulite affects approximately 80% to 98% of adult women, with most sources citing 80-90% of post-pubertal women and results from fibrous septa pulling the dermis downward while fat pushes upward, creating visible dimples. The condition reflects the structure of the connective tissue, not a person’s weight or fitness level. Avéli, developed by Revelle Aesthetics and FDA-cleared under 510(k) number K221336 on August 5, 2022, uses a Targeted Verifiable Subcision (TVS) approach. The provider inserts a thin probe through a tiny puncture, uses an integrated LED light to visualize the probe tip beneath the skin, deploys a manual hook to capture each individual septum, confirms capture by observing the dimple pull down, then cuts the band with a manual blade. Real-time visual and tactile confirmation helps ensure each dimple is fully released before the provider moves to the next.
Avéli mechanically severs the physical cause of each dimple in a single session, unlike energy-based treatments that only heat or remodel tissue near the surface. It specifically targets dimples caused by septa tethering, rather than skin laxity or excess fat.
Discuss Your Cellulite Concerns With A Board-Certified Surgeon at Mirror Plastic Surgery to see whether Avéli is the right structural solution for your cellulite.
The Pivotal Evidence: What The CONFFIRM Study Shows
The CONFFIRM study (NCT04743635), a single-arm, multicenter, open-label pivotal trial published by Stevens et al. in the Aesthetic Surgery Journal (2023), is the main clinical evidence base for Avéli. Researchers followed patients for 12 months after a single treatment session. Key findings include:
- Cellulite Severity Scale (CSS) Improvement: Mean improvement of 1.50 points at 3 months and 1.48 points at 12 months, showing sustained benefit through the full study period.1 The 6-month measurement showed a mean improvement of approximately 1.54 points, consistent with this trajectory.
- Global Aesthetic Improvement Scale: 95.6% of patients showed improvement, and 80% were rated “much improved” or “very much improved” at 3 months.1
- Patient Satisfaction: Satisfaction reached 93% at 12 months, up from 80% at 3 months, suggesting that results often look better as tissues heal and settle.1
- Adverse Events: Most patients experienced bruising, typically mild to moderate, with soreness and mild edema in roughly half. These effects resolved without intervention. No serious, unanticipated, or severe adverse events were reported.
The study’s follow-up ends at 12 months, and there is no published peer-reviewed data tracking Avéli patients beyond one year. The evidence is strong through 12 months. Claims of multi-year durability rely on the mechanism and on data from similar devices, rather than on Avéli-specific long-term studies.
How Long Results Last: Interpreting “Permanent”
Once a fibrous septum is cut, it retracts and does not reconnect. This non-reattachment of treated septa explains why corrected dimples should not return and mirrors the durability seen in the analogous Cellfina three-year follow-up data (Kaminer et al., 2017).1 For Avéli itself, published evidence currently extends to 12 months.
“Permanent” needs three clear qualifiers:
- Aging Changes Skin: Natural aging thins the dermis and reduces elasticity. These changes can alter overall skin texture in treated areas over time.
- Weight Fluctuations Matter: Significant weight gain or loss changes the fat compartment beneath the skin. These shifts can create new dimples in untreated areas or change the look of treated regions.
- New Dimples Can Form: The procedure releases specific septa and does not block the formation of new fibrous bands elsewhere if the structural environment changes.
Avéli provides long-term structural correction of treated dimples. Clinical data supports improvement through at least 12 months, and the mechanism suggests durability beyond that timeframe.1 It does not stop the natural aging process or the effects of major weight changes. Maintaining results involves stable weight, consistent exercise, hydration, balanced nutrition, and healthy skin practices.
After understanding durability, it helps to see how Avéli compares with other cellulite treatments on mechanism, evidence, and recovery.
Comparative Analysis: Avéli Vs. Alternative Cellulite Treatments
To understand Avéli’s role in cellulite care, compare it with the main alternatives: Cellfina, energy-based devices, topical creams, and injectable enzymes. Focus on how each works, how many sessions they require, and how long results last.
Avéli Vs. Cellfina: Cellfina uses vacuum-stabilized subcision with a motorized reciprocating microblade at a fixed depth. This “blind” technique cuts all tissues within the vacuum chamber. It can lead to significant post-treatment bruising, swelling, and fluid accumulation. Avéli’s light-guided, manual hook system allows real-time verification of each septa release with less tissue trauma. FDA MAUDE database analysis (extract dated June 2026) shows 30 adverse event reports for Avéli versus 49 for Cellfina. Cellfina has published three-year follow-up data, while Avéli’s published evidence currently extends to 12 months. Typical recovery is one to two weeks for Avéli and two to four weeks for Cellfina.
Avéli Vs. Laser And Radiofrequency Treatments: Energy-based treatments require multiple sessions, usually four to six for radiofrequency and six to twelve for acoustic wave, for gradual, temporary improvement. These devices heat or remodel tissue near the surface and do not physically release the septa that cause dimples. Results fade as tissue naturally remodels.
Avéli Vs. Topical Creams: Topical products cannot reach the fibrous bands. They provide temporary cosmetic smoothing at the skin’s surface without changing the underlying structure.
Avéli Vs. Injectable Enzymes (Qwo): Qwo was voluntarily withdrawn from the U.S. market in 2023 for commercial reasons, and clinical trials showed high rates of injection-site pain, bruising, and nodules. It is no longer available.
Avéli is described as the first and only cellulite device that allows real-time identification and release of septa with confirmation and has published 12-month efficacy data.
Explore Whether Avéli Or Another Option Fits Your Goals by reviewing your anatomy and treatment history with Mirror Plastic Surgery.
Risk Profile And Safety Analysis
Online forums often highlight dissatisfaction or prolonged side effects from cellulite treatments. Clinical and regulatory data provide a clearer picture of Avéli’s safety profile.
From the CONFFIRM study, the following adverse event profile was documented:
- Common (Most Patients): Bruising or ecchymosis, typically mild to moderate, resolving without intervention.
- Common (Roughly Half Of Patients): Soreness or tenderness and mild edema, all resolving without intervention.
- Less Common: Small areas of firmness, usually not visible or painful, typically resolving within a couple of months, and temporary hyperpigmentation.
- Rare (From MAUDE Database): Persistent bruising, induration, nodules, and rare infections, with 30 total reports for Avéli through June 2026. MAUDE passive reports do not represent true incidence rates and cannot prove causality.
The provider factor plays a central role in both safety and cosmetic outcome. Avéli requires precise anatomical knowledge to avoid contour irregularities, identify the correct septa, and achieve complete release. Because of this need for precision, it suits practitioners with surgical understanding of subcutaneous architecture rather than casual or occasional users.
Clinical Recommendations: Candidacy And Provider Selection
Optimal candidates are adult women with visible cellulite dimples on the buttocks or thighs, at or near stable body weight, with good skin elasticity, a BMI of 30 or less, who do not smoke, have not had liposuction in the treatment area, and understand that Avéli treats dimples rather than skin laxity or fat.
Provider expertise is the single most important variable in outcomes and safety. Avéli requires the provider to identify which septa contribute to each dimple, cut precisely without damaging surrounding tissue, and verify complete release in real time. These demands align with the type of anatomical mastery that comes from surgical training. Dr. Akash Chandawarkar exemplifies this expertise. He is a board-certified plastic surgeon, Harvard-educated and Johns Hopkins-trained, and serves on the advisory board for Tiger Aesthetics, the manufacturer of Avéli, which gives him direct insight into the device’s design and clinical application.
Schedule A Personalized Avéli Candidacy Evaluation at Mirror Plastic Surgery in St. Petersburg to review your anatomy, goals, and treatment options.
Conclusion: Key Takeaways
- Avéli works by mechanically releasing the fibrous septa that cause cellulite dimples, creating a structural correction rather than a surface-only effect.
- The CONFFIRM pivotal study demonstrates meaningful and sustained improvement on the Cellulite Severity Scale and high patient satisfaction at 12 months after a single session.
- “Permanent” refers to the non-reattachment of treated septa, while aging and weight changes can still create new dimples or alter skin texture over time.
- Published evidence for Avéli extends through 12 months, and longer-term peer-reviewed data has not yet been released.
- Surgical-level anatomical expertise in the treating provider is the key factor in both safety and cosmetic outcome.
Frequently Asked Questions
Is Avéli Worth It?
The CONFFIRM study shows high satisfaction at 12 months and sustained improvement on the Cellulite Severity Scale after a single session, and most participants considered treatment worthwhile.1 Whether Avéli makes sense for you depends on cellulite severity, expectations, and comfort with temporary bruising and downtime. A consultation with a qualified surgical provider allows an individualized assessment based on your anatomy. At Mirror Plastic Surgery, Dr. Akash Chandawarkar focuses on honest, evidence-based guidance, including advising against treatment when it does not fit a patient’s anatomy or goals.
How Long Does Avéli Last?
Published clinical evidence from the CONFFIRM study shows improvement sustained through 12 months, which matches the full duration of the pivotal trial. The non-reattachment of treated septa and three-year data from the similar Cellfina device support the expectation of durable results, although Avéli-specific data beyond 12 months has not yet been published.1 Aging and significant weight changes can still create new dimples or change skin texture over time, independent of previously treated areas.
Does Avéli Hurt?
The procedure uses local anesthesia, so discomfort during treatment is usually minimal. In the CONFFIRM clinical study, mild pain within the first 24 hours was common, with bruising and tenderness typically resolving within 30 days. Small areas of firmness, usually not visible or painful, resolved within a couple of months. Most patients resumed normal activities within 24 to 48 hours. Strenuous lower-body exercise is typically avoided for one to two weeks so underlying tissues can heal properly.
What Actually Gets Rid Of Cellulite?
The only treatments with published evidence of durable improvement are subcision-based procedures, such as Avéli, that physically release the fibrous septa causing dimples. Topical creams cannot reach the fibrous bands and provide only temporary surface smoothing. Energy-based devices like radiofrequency and acoustic wave therapy require multiple sessions and produce gradual, temporary improvement that fades as tissue remodels. Injectable enzyme treatment Qwo was voluntarily withdrawn from the U.S. market in 2023 for commercial reasons, and clinical trials reported high rates of injection-site pain, bruising, and nodules. Avéli is currently the only FDA-cleared single-session device with published 12-month efficacy data for structural dimple correction.
How Much Does Avéli Cost?
Cost varies based on the number of dimples treated and the details of your treatment plan. At Mirror Plastic Surgery, every patient receives a personalized assessment. Dr. Akash Chandawarkar evaluates your anatomy, dimple count, and goals before discussing any treatment plan or pricing. A personalized quote is provided during consultation. Contact Mirror Plastic Surgery at 727-361-6515 or hello@mirrorplasticsurgery.com, or book your consultation online to get started.
Disclaimer: Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
1 Results may vary from person to person. Editorial content, before and after images, and patient testimonials do not constitute a guarantee of specific results.
